CClinicalTrials.gg
CompletedNCT03269643Updated Apr 16, 2019

Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients Patients

An interventional study of Investigational Group and Reference group in Vital Sign Monitoring, sponsored by Darma Inc.. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Darma Inc. · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Sex
All
01

Study summary

This study comparing both of the investigational device and reference device to gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring. The primary variables for the analysis of heart rate (HR) and respiratory rate (RR) are each the overall mean root mean square difference (RMSD). Results of the investigational device and reference device compared with the patient monitor are evaluated to see if there are equivalent. Motion and bed exit accuracy will be evaluated by comparing with the manual observation.

Read the detailed description

The testing will be conducted in three periods. In the Accuracy Tests (periods

1 and 2), one of the contact-free devices will be used to monitor the HR and RR, while being compared with the Patient Monitor. The RHEA investigational device and reference device will be used to monitor the same subject at different times, as the sensors of the two devices are placed at a similar location of the bed. HR and RR will be recorded for all three devices.

The primary hypotheses for HR, are as follows:

Adults HO: μ = 3.25 vs. HA: μ \< 3.25, Children HO: μ = 3.5 vs. HA: μ \< 3.5,

The primary hypotheses for RR, are as follows:

Adults HO: μ = 2.25 vs. HA: μ \< 2.25, Children HO: μ = 2.5 vs. HA: μ \< 2.5, where μ represents the population mean HR or RR. If the upper bound of the confidence interval is less than the hypothesized value, the corresponding null hypothesis will be rejected. Comparison of the performance of the two contact-free devices will be performed on the recorded results via statistical analysis.

The hypothesis here is that the two devices have equivalent performance. The third test will assess the ability of the RHEA device to accurately detect motion on or exit from the bed, as compared to the manual observation. Motion and no motion accuracy will each be calculated along with their respective two-sided 95% confidence intervals.

02

Conditions studied

  • Vital Sign Monitoring

Keywords

  • Vital Sign
  • Vigilance System
  • Heart Rate
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female, 18 years old and above.
  2. Provide written informed consent.
  3. Weight ranging from 20 to 150 kg inclusive.
  4. Are located in a non-ICU hospital setting.
  5. Agree to not eat during the testing period.
  6. Agree to keep still.

Exclusion criteria

Exclusion Criteria:

  1. Are connected to a device which may interfere with the device monitoring in this study.
  2. Are receiving any bedside care which may be incompatible with the study procedures.
  3. Sleep apnea.
  4. Pregnant or breastfeeding.
  5. A likely need to receive or undergo a procedure during the testing period.
  6. Cannot accept a nasal cannula, or have a monitor lead placed on the chest.
  7. A significant medical condition in the judgement of the investigator, which may compromise the study testing procedures.
  8. Are wearing pacemaker or defibrillator.
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Investigational Group

    The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

    Device: Investigational Group

  • Active comparator
    Reference Group

    The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

    Device: Reference group

Interventions

  • DeviceInvestigational Group

    The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

  • DeviceReference group

    The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

05

What researchers measure

Primary outcomes

  1. RMSD of Investigational Device's Heart Rate and Gold Standard Device's heart rate

    Record 20 valid pair heart rate displayed in the investigational device and patient monitor at the same time every one minutes.Calculate the root mean square difference(RMSD) of the heart rate for the investigational device.

    Time frame: 30 days

  2. RMSD of Investigational Device's Respiratory Rate and Gold Standard Device's Respiratory rate

    Record 20 valid pair respiratory rate displayed in the investigational device and patient monitor at the same time every one minutes.Calculate the root mean square difference(RMSD) of the respiratory rate for the investigational device.

    Time frame: 30 days

Secondary outcomes

  1. Heart Rate t Test Comparison result between the Investigational Device and the Reference Device

    Record 20 valid heart rate displayed in the reference device and patient monitor at the same time every one minute. Calculate the t test results for heart rate for the reference device and the investigational device.

    Time frame: 30 days

  2. Respiratory Rate t Test Comparison result between the Investigational Device and the Reference Device

    Record 20 valid respiratory rate displayed in the reference device and patient monitor at the same time every one minute. Calculate the t test results for respiratory rate for the reference device and the investigational device.

    Time frame: 30 days

  3. Motion Notification Accuracy(%)

    Record the time for each instructed movements from manual observation and time for movements notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.

    Time frame: 30 days

  4. Bed Exit Notification Accuracy(%)

    Record the time for each instructed bed exit from manual observation and time for bed exit notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.

    Time frame: 30 days

06

Study locations

1 site
  • MedStar Health Research Institute, Inc.
    Washington, District of Columbia 20770, United States
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 7, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03269643
Lead sponsor
Darma Inc.
Collaborators
Medstar Health Research Institute
Responsible party
Sponsor
First posted
Sep 1, 2017
Start date
Sep 1, 2017
Primary completion
Nov 24, 2017
Completion
Nov 24, 2017
Last update
Apr 16, 2019

Study contacts

Arrel Olano, MD
principal investigator · Medstar Health Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion